Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andy Tran

Clinical Cardiac Electrophysiology Surprise, AZ Medical Doctor

NPI 1295781029 CMS profile 195452

12361 W Bola Dr Ste 100, Surprise, AZ 85378

Open in the dashboard

General payments

$124,986

765 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,700 paid to institutions, not to them · program years 2019–2020

Through program year 2025, Andy Tran of Surprise, AZ is reported in the CMS Open Payments database as having received $124,986 across 765 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,700 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18,010 87
2024 General $18,261 100
2023 General $12,648 93
2022 General $12,862 99
2021 General $4,409 96
2020 General $20,149 111
2019 General $38,647 179

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andy Tran
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Andy Tran were reported at $18,010. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Andy Tran Clinical Cardiac Electrophysiology median Middle half National median
2019 $38,647 $2,361 $585–$8,260 $163
2020 $20,149 $993 $247–$4,351 $114
2021 $4,409 $1,185 $326–$4,739 $132
2022 $12,862 $2,073 $554–$6,789 $149
2023 $12,648 $2,568 $759–$8,159 $160
2024 $18,261 $2,557 $703–$7,403 $164
2025 $18,010 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $72,781 364 payments
  2. Abbott Laboratories $35,946 152 payments
  3. Impulse Dynamics (USA) Inc. $7,634 16 payments
  4. Biotronik Inc. $3,102 18 payments
  5. Biosense Webster, Inc. $1,534 31 payments
  6. Cardiva Medical, Inc. $584 21 payments
  7. Edwards Lifesciences Corporation $461 6 payments
  8. Pfizer Inc. $345 22 payments
  9. Bardy Diagnostics, Inc. $300 11 payments
  10. Janssen Pharmaceuticals, Inc $259 21 payments
  11. Other $2,040 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $65,750 85 payments
  2. Consulting Fee $35,947 48 payments
  3. Food and Beverage $16,985 620 payments
  4. Honoraria $3,000 1 payment
  5. Grant $1,667 1 payment
  6. Travel and Lodging $1,379 7 payments
  7. Education $258 3 payments
Products named General payments · program years 2019–2025
  1. GENERAL BRADY $14,030 23 payments
  2. GENERAL - BRADY Brady $12,500 23 payments
  3. Quadra Assura CRT Defibrillator $10,495 19 payments
  4. Quadra Allure MP RF CRT Pacemkr $9,416 20 payments
  5. General - Brady General - Brady_CRM $5,715 9 payments
  6. Allure Quadra RF CRT Pacemaker $4,243 7 payments
  7. EMBLEM MRI S-ICD $3,908 6 payments
  8. Accent Pacemaker $3,824 6 payments
  9. General Tachy $3,766 4 payments
  10. Optimizer $3,062 5 payments
  11. Other $27,477 573 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

4,529

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,139,692

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

33.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 480 $626,117
Xarelto Rivaroxaban Brand 114 $153,734
Farxiga Dapagliflozin Propanediol Brand 64 $82,690
Entresto Sacubitril/Valsartan Brand 52 $78,775
Jardiance Empagliflozin Brand 37 $47,754
Multaq Dronedarone Hcl Brand 17 $34,468
Metoprolol Succinate Generic 592 $12,716
Flecainide Acetate Generic 207 $12,091
Repatha Sureclick Evolocumab Brand 19 $11,032
Dofetilide Generic 58 $9,377

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 84 billing codes

Paid by Medicare

$1,038,274

Of which drugs: $1,195

Medicare patients

1,139

Average age 77

Services billed

11,877

509 women, 630 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 59%
Arthritis 46%
Ischemic heart disease 40%
Heart failure 31%
Chronic kidney disease 31%
Diabetes 27%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 104 420 $1,195

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYNDAQEL
$70 — —
CAMZYOS
$37 — —
Arcalyst
$31 — —
ELIQUIS
$20 480 —
LEQVIO
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

765 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record